| abstract |
FIELD: medicine; pharmaceuticals. n SUBSTANCE: invention relates to a compound of formula I-b: n n n n (Formula I-b), n where L is SO 2 , each R 1 and R 2 is independently selected from a group consisting of H and C 1-4 alkyl; R 3 is selected from a group consisting of C 1-3 alkyl, optionally substituted with R 21 ; ring is selected from a group consisting of n , , , , , , , , , , and $ ; each R 4 , R 5 , R 7 and R 8 is independently selected from a group consisting of H, F, Cl, Br, C 1-4 alkyl, N 3 , NH 2 , CF 3 , OCHF 2 , OCF 3 , OC 1-4 alkyl, benzoyl, -OCH 2 C≡CH, CN, and NO 2 ; R 6 is selected from a group consisting of H, Br and R 17 ; R 9 is H; R 10 is H or Br; each R 11 , R 12 and R 13 independently represents H, F, Cl or Br; each R 14 , R 15 and R 16 independently represents H, methyl or ethyl; R 17 is phenyl, optionally substituted with one or more substitutes selected from the group consisting of NO 2 and -NR 18 CO-(C 1-4 alkyl); each R 18 independently represents H; each R 21 is independently selected from a group, consisting of H, CN and OR 22 ; each R 22 independently represents H; and to compounds of similar structure, presented by specific chemical formulas, as well as to a pharmaceutical composition for treating colon cancer, comprising a therapeutically effective amount of such compounds, and a method of treating colon cancer. n EFFECT: therapeutic agents aimed at truncated proteins of adenomatous polyposis coli (APC) are proposed. n 9 cl, 62 dwg, 1 tbl, 3 ex |